- Title
- WED-371 Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment
- Creators
- Man-Fung YuenJeong HeoRonald G. NahassGrace Lai-Hung WongTatiana BurdaKalyan Ram BhamidimarriTsung-Hui HuTuan T. NguyenYoung-Suk LimChi-Yi ChenStuart C. GordonJacinta HolmesWan-Long ChuangAnita KohliNaim AlkhouriKevin GrayEmily P. ThiElina MedvedevaTimothy EleySharie C. GanchuaChristina IottElizabeth EillChristine L. EspirituMark AndersonTiffany FortneyGavin ClohertyKaren D. Sims
- Publication Details
- Journal of hepatology, Vol.80, pp.S809-S810
- Publisher
- Elsevier B.V
- Identifiers
- 991006093671802656
- Academic Unit
- Internal Medicine
- Language
- English
- Resource Type
- Journal article
Journal article
WED-371 Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment
Journal of hepatology, Vol.80, pp.S809-S810
06/2024
Metrics
2 Record Views